Question 1

What is Trevogrumab?

Accepted Answer

Trevogrumab is a monoclonal antibody developed by Regeneron Pharmaceuticals that blocks myostatin (GDF-8), the protein that limits muscle growth. It has gained significant attention in the peptide/biohacking community because Phase II trials showed it could preserve approximately half of the muscle mass normally lost during rapid GLP-1-mediated weight loss.

Question 2

What are the research benefits of Trevogrumab?

Accepted Answer

Research on Trevogrumab has investigated its potential effects in several areas, including: Preserved ~50% of muscle loss during GLP-1 weight loss in Phase II; Addresses the biggest criticism of GLP-1 drugs (muscle wasting); Potent myostatin inhibition via monoclonal antibody; Potential to pair with semaglutide/tirzepatide for optimized body composition. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does Trevogrumab work?

Accepted Answer

Trevogrumab binds to circulating myostatin and prevents it from activating its receptor (ActRIIB) on muscle cells. Myostatin is a negative regulator of muscle growth — it signals muscles to stop growing. By neutralizing myostatin, trevogrumab removes this brake, allowing muscle protein synthesis and satellite cell recruitment to continue even during caloric deficit or GLP-1-mediated weight loss.

Question 4

What is the FDA/legal status of Trevogrumab?

Accepted Answer

Trevogrumab is currently in clinical trials and is not yet FDA-approved for general use. It may only be used in the context of approved clinical trial protocols. It is not available for general consumer purchase in the United States.

Question 5

What are the known risks or side effects of Trevogrumab?

Accepted Answer

Based on available research, Trevogrumab has been associated with the following in study settings: Injection site reactions; Potential for tendon/joint issues from rapid muscle growth; Diarrhea (reported in some trial participants); Full safety profile not yet established. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on Trevogrumab?

Accepted Answer

Published research on Trevogrumab can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "Trevogrumab" or its aliases (REGN1033, Anti-myostatin antibody) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

Trevogrumab

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer